Evolus (NASDAQ:EOLS) Shares Down 5.5% on Insider Selling

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price traded down 5.5% during trading on Tuesday following insider selling activity. The company traded as low as $9.31 and last traded at $9.42. 110,433 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 938,410 shares. The stock had previously closed at $9.96.

Specifically, insider David Moatazedi sold 16,582 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.89, for a total value of $163,995.98. Following the completion of the sale, the insider now directly owns 364,927 shares of the company's stock, valued at $3,609,128.03. This trade represents a 4.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Moatazedi sold 111,323 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $10.05, for a total value of $1,118,796.15. Following the transaction, the insider now directly owns 381,509 shares in the company, valued at $3,834,165.45. This represents a 22.59% decrease in their position. The disclosure for this sale can be found here.

Analyst Ratings Changes

EOLS has been the subject of a number of research reports. Barclays lifted their price target on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $23.75.

Evolus Stock Performance

The company has a market cap of $598.37 million, a price-to-earnings ratio of -10.43 and a beta of 1.00. The company has a quick ratio of 2.16, a current ratio of 2.34 and a debt-to-equity ratio of 22.00. The stock has a 50 day simple moving average of $10.27 and a 200 day simple moving average of $11.68.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. AlphaQuest LLC purchased a new stake in shares of Evolus during the first quarter worth about $39,000. State of Wyoming grew its position in shares of Evolus by 988.1% during the first quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after buying an additional 3,409 shares in the last quarter. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Evolus during the fourth quarter valued at approximately $106,000. Finally, Rafferty Asset Management LLC bought a new position in Evolus during the fourth quarter worth $115,000. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.